Page last updated: 2024-09-04

naproxen and Cardiovascular Diseases

naproxen has been researched along with Cardiovascular Diseases in 73 studies

Research

Studies (73)

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (2.74)	18.7374
1990's	0 (0.00)	18.2507
2000's	37 (50.68)	29.6817
2010's	28 (38.36)	24.3611
2020's	6 (8.22)	2.80

Authors

Authors	Studies
Bao, W; Davey, DA; Husni, E; Libby, P; Lüscher, TF; Nissen, SE; Obeid, S; Ruschitzka, F; Walker, C; Wang, Q; Wisniewski, LM; Wolski, KE; Xia, F	1
Husni, ME; Minhas, D; Nidhaan, A	1
A Katouah, H; Acker, M; Al Hadi, R; Ali, M; Alserihi, R; Alyami, J; Alzahrani, E; Amirazodi, M; Amrillah, T; Andreassen, OA; Ardiccioni, C; Ask, H; Atzori, C; Ayorech, Z; Azambuja, JH; Azmi, R; Badem, S; Balci, AB; Bali, H; Baranova, NS; Barantsevich, ER; Barocci, S; Bauer, RJ; Bauermeister, JA; Bazhenova, TA; Biagetti, G; Bigdeli, F; Bonar, EE; Bouloumis, T; Bu, Y; Cai, Z; Cakiroglu, B; Canetto, SS; Cao, J; Caucci, S; Cerbo, I; Chen, C; Chen, J; Chen, Q; Chen, Y; Cheng, B; Cheng, X; Chinappi, M; Choya, A; Cicconardi, F; Cipolletta, S; Colasurdo, G; Costabile, BK; Coughlin, LN; Crippa, P; D'Agostino, M; D'Annessa, I; Daryanoosh, F; Das, R; Davey Smith, G; Davidson, BR; Davies, NM; Davis, TME; Davis, WA; de Rivas, B; Demir, D; Deng, Z; Dhanya, TM; Di Marino, D; Divya, KM; Dong, N; Drinkwater, JJ; Ekholuenetale, M; El-Bindary, AA; El-Bindary, MA; El-Desouky, MG; Elsayed, H; Ema, K; Endraswari, PD; Entilli, L; Ettl, T; Eyado, A; Fan, X; Fang, W; Farina, M; Florimbio, AR; Fowobaje, KR; Gaeini, A; Gao, XM; Gao, Y; Ghaemi, R; Ghelardi, E; Gilmutdinov, IF; Gochicoa-Rangel, L; Goncu, MT; Gözüküçük, R; Grammatikopoulos, P; Gu, Y; Guan, ZJ; Gucu, A; Guldberg, R; Gungor, O; Guo, W; Gutiérrez-Ortiz, JI; Guzmán-Boulloud, N; Guzmán-Valderrábano, C; Głuszko, A; Hama, A; Hamada, M; Han, J; Hashimoto, T; Havdahl, A; Hayashita, T; He, X; Helgeland, Ø; Hinck, AP; Hinck, CS; Holtzapple, M; Hou, Y; Howe, LD; Hu, B; Hu, H; Huang, L; Huang, Z; Hughes, AM; Hussain, G; Ibidoja, OJ; Ichikawa, D; Imber, C; Islam, MR; Iype, S; Jaber, J; Jacobs, R; Jafry, AT; Ji, L; Ji, X; Jiang, L; Jiang, Y; Jie, HFM; Jie, HM; Johansen, MP; Johansson, S; Juan, LX; Juan, W; Kahraman, N; Kallinger, I; Kang, H; Karakulova, YV; Kärmer, T; Kataoka, S; Kato, K; Kawashima, N; Kazim, AH; Khalil, MR; Kitazawa, H; Klimesova, YM; Kojima, S; Kose, M; Kostakis, ID; Koushkie Jahromi, M; Krishna, GA; Krizova, D; La Teana, A; Lan, K; Li, J; Li, JZ; Li, M; Li, R; Li, S; Li, Y; Li, Z; Liu, H; Liu, J; Liu, KG; Liu, L; Liu, Q; Liu, T; Liu, X; Lomachenko, KA; López-Fonseca, R; Ludwig, N; Luo, A; Luo, L; Luo, Y; Lupetti, A; M El-Metwaly, N; Ma, K; Maemura, R; Magnus, P; Manakin, YV; Mancia, F; Mashood, LO; Matsumoto, K; Mehrabi, A; Meier, JK; Mekonnen, Y; Mencarelli, D; Menzo, S; Mikagi, A; Mironov, VS; Misawa-Suzuki, T; Miwata, S; Mizuta, Y; Mohanan, PV; Mondal, J; Morici, P; Morita, K; Morozzo Della Rocca, B; Morris, T; Morsali, A; Morzhukhina, MV; Motta, S; Muramatsu, H; Naidu, R; Narita, A; Narita, K; Nasralla, D; Nemcokova, M; Netukova, M; Nishikawa, E; Nishio, N; Niu, X; Niu, Y; Njølstad, P; Notarstefano, V; Nugroho, MA; Nørgård, BM; Okuno, Y; Olokede, O; Ong, SP; Osailan, A; Ouyang, Z; Ozyazicioglu, AF; Pan, F; Parui, A; Paul, R; Pavoni, E; Payne, TE; Peng, X; Pérez-Padilla, R; Perta, N; Peter, SC; Pierantoni, L; Pietrowska, M; Pissanou, T; Pollok, JM; Prasetio, A; Putra, FS; Qiang, C; Qiao, L; Qutob, HMH; Raptis, DA; Razzo, BM; Reichborn-Kjennerud, T; Reichert, TE; Remigio-Luna, A; Rexha, J; Rivani, E; Rizzato, C; Romagnoli, A; Rossolini, GM; Sa, LY; Saad, RA; Sakaguchi, H; Salesi, M; Salsabilla, Z; Sanderson, E; Sanderson, P; Savitha, DP; Schulz, D; Seker, IB; Selvaganapathy, PR; Sha, D; Shah, SF; Shaikhomar, OA; Sharma, D; Shi, C; Shi, P; Shrotri, A; Sidiq, DH; Simonov, SV; Singh, AK; Song, C; Song, T; Spanier, G; Spoerl, S; Staropoli, A; Statsenko, ME; Steinhauer, S; Stosic, A; Studeny, P; Sugaya, T; Sun, S; Sun, X; Sunbul, SA; Supandi, AR; Suzuki, K; Suzuki, Y; Szczepański, MJ; Takahashi, Y; Taniguchi, R; Tao, Y; Tesli, M; Thirión-Romero, I; Tong, D; Trucchi, E; Tsuchido, Y; Turchetti, C; Turkina, SV; Turner, AW; Uldbjerg, N; Vinale, F; Wakamatsu, M; Walton, MA; Wang, C; Wang, Q; Wang, W; Wang, Y; Wang, Z; Wehberg, S; Wei, ZL; Wen, B; Whiteside, TL; Whittingham, MS; Widodo, ADW; Widłak, P; Wright, AI; Wu, H; Wu, Y; Wu, YL; Xiang, LG; Xiao, G; Xie, B; Xie, L; Xin, H; Xiong, J; Xiong, X; Xu, C; Xu, S; Yagubskii, EB; Yakushev, IA; Yang, H; Yang, J; Yao, J; Yao, ZX; Ye, J; Yerneni, SS; Yirgu, A; Yoshida, N; Yoshida, T; Young, SD; Yu, DN; Yuksel, A; Zac, J; Zac, S; Zarifkar, AH; Zhai, Y; Zhang, F; Zhang, H; Zhang, JW; Zhang, L; Zhang, Q; Zhang, X; Zhang, Y; Zhao, D; Zhao, J; Zhao, M; Zheng, D; Zheng, J; Zhou, G; Zhou, H; Zhu, P; Zhu, T; Zhu, Y; Zimmerman, MA; Zou, X	1
Lane, NE; Lei, G; Li, X; Wei, J; Zeng, C; Zhang, Y	1
Bonnesen, K; Ehrenstein, V; Grønkjær, MS; Hallas, J; Lash, TL; Pedersen, L; Schmidt, M; Sørensen, HT	1
Ernst, MT; Hallas, J; Pottegård, A; Schmidt, M	1
de Nucci, G; Dicay, M; MacNaughton, WK; Vaughan, D; Wallace, JL	1
Raschle, J	1
Au, KWL; Chan, FKL; Chan, H; Cheong, PK; Ching, JYL; Kee, KM; Kyaw, MH; Lam, K; Lee, V; Lo, A; Ng, SC; Suen, BY; Tse, YK; Wong, GLH; Wong, VWS; Wu, JCY	1
Hyun, MK; Woo, Y	1
Ganju, J; Rom, D	1
Bao, W; Berger, MF; Borer, JS; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND	1
Pedersen, L; Schmidt, M; Sørensen, HT	1
Buschiazzo, HO; Cañás, M; Dorati, CM; Mordujovich-Buschiazzo, P; Prozzi, GR; Urtasun, MA	1
Husni, ME; Nissen, S; Paynter, N; Shao, M; Solomon, DH; Wolski, K	1
Nissen, SE; Reed, GW	1
Spitz, S	1
Dubost, JJ; Lahaye, C; Mathieu, S; Rosenbaum, D; Soubrier, M; Tatar, Z	1
Sifferlin, A	1
Harbin, M; Kolber, MR; Turgeon, RD	1
Tjwa, ET; van den Bemt, P; van Oijen, MG	1
Ariano, C; Baldi, C; Cantatrione, S; Cioppa, C; De Vecchis, R; Di Biase, G; Giasi, A; Valente, L	1
Gemici, B; Wallace, JL	1
Horváth, VJ; Koós, CG; Lakatos, P; Putz, Z; Szabó, G; Tabák, GÁ	1
Anwar, A; Anwar, IJ; Delafontaine, P	1
Angiolillo, DJ; Weisman, SM	1
Bao, W; Beckerman, B; Berger, MF; Borer, JS; Gaffney, M; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Ruschitzka, F; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND	1
González-Gay, MA; González-Juanatey, C	1
Castelli, G; King, D; Petrone, A; Shrader, C; Xiang, J	1
Kapoor, JR	1
Hermann, M	1
Becker, MC; Borer, JS; Graham, DY; Husni, ME; Krum, H; Libby, P; Lincoff, AM; Lüscher, TF; Mascette, AM; Nissen, SE; Ruschitzka, F; Solomon, DH; Wang, TH; Wisniewski, L; Wolski, K; Yeomans, ND	1
Arbogast, PG; Castellsague, J; Chung, CP; Daugherty, JR; García-Rodríguez, LA; Murray, KT; Ray, WA; Stein, CM; Varas-Lorenzo, C	1
Baker, LD; Breitner, JC; Milne, G; Montine, TJ; Sonnen, JA	1
Henry, D; McGettigan, P	2
Bansal, M; Happich, M; Klein, R; Wielage, R; Wilson, K	1
Adly, G; Plakogiannis, R	1
Dixon, ME; Geba, GP; Johansson, G; Lisse, JR; Mollen, AJ; Perlman, M; Polis, AB; Schechtman, J; Shoemaker, JR; Skalky, CS	1
Brune, K	1
Fitzgerald, GA	1
Arellano, FM	1
Capone, ML; Di Gregorio, P; Grana, M; Merciaro, G; Patrignani, P; Renda, G; Ricciotti, E; Sciulli, MG; Tacconelli, S	1
Lehmann, DF	1
Konstantinopoulos, PA; Lehmann, DF	1
Braunstein, N; Polis, A	1
Frazier, KC	1
Burnier, M; Mathieu, C; Meier, P; Meyer zu Starten, A	1
Hazleman, BL; Ostor, AJ	1
Curfman, GD; Drazen, JM; Morrissey, S	1
Bombardier, C; Burgos-Vargas, R; Davis, B; Day, R; Ferraz, MB; Hawkey, CJ; Hochberg, MC; Kvien, TK; Laine, L; Schnitzer, TJ; Weaver, A	1
Geisslinger, G; Tegeder, I	1
Antonelli, E; Fiorucci, S	1
Barner, JC; Busti, AJ; Lawson, KA; Motsko, SP; Rascati, KL; Wilson, JP; Worchel, J	1
Gregor, P; Ormiston, TM; Raina, P; Salpeter, SR; Thabane, L; Topol, EJ; Whitlock, R	1
Cady, R; Schreiber, C	1
Castellsague, J; Maguire, A; Perez-Gutthann, S; Varas-Lorenzo, C	1
Häussler, B; Höer, A	1
Deray, G; Montalescot, G; Sibilia, J	1
Flipo, RM	1
Bergman, G; Curtis, SP; Ko, AT; Malmstrom, K; Mehta, A; Reginster, JY; Reicin, AS	1
Abramson, SB; Chesebro, JH; Farkouh, ME; Fuster, V; Greenberg, JD; Hochman, JS; Jeger, RV; Kirshner, H; Lay, CL; Matchaba, PT; Mellein, B; Ramanathan, K; Ruland, S; Verheugt, FW	1
Amer, F; Cryer, B; Goldstein, JL; Hunt, B	1
Borzak, S; Hennekens, CH	1
Bombardier, C; Burgos-Vargas, R; Davis, B; Day, R; Ferraz, MB; Hawkey, CJ; Hochberg, MC; Kvien, TK; Laine, L; Reicin, A; Schnitzer, TJ; Shapiro, D	1
Tive, L	1
Barr, E; Gertz, BJ; Konstam, MA; Reicin, A; Shapiro, D; Sperling, RS; Weir, MR	1
Fraunfelder, FT	1
Giercksky, KE; Herland, OB; Holme, I; Husby, G; Rugstad, HE	1

Reviews

27 review(s) available for naproxen and Cardiovascular Diseases

Article	Year
Recommendations for the Use of Nonsteroidal Anti-inflammatory Drugs and Cardiovascular Disease Risk: Decades Later, Any New Lessons Learned? Rheumatic diseases clinics of North America, 2023, Volume: 49, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Humans; Ibuprofen; Naproxen	2023
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease. Medicina clinica (English ed.), 2022, Dec-23, Volume: 159, Issue:12 Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter Infections; Adaptation, Psychological; Adolescent; Adsorption; Adult; Aged; Alcohol Drinking; Alzheimer Disease; Amikacin; Ammonia; Anaerobiosis; Animals; Anorexia; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Anxiety; Aptamers, Nucleotide; Asthenia; Attention Deficit Disorder with Hyperactivity; Bacterial Proteins; Beryllium; beta-Lactamases; Biofuels; Biomass; Biosensing Techniques; Bismuth; Blister; Body Mass Index; Body Surface Area; Boronic Acids; Brain; Breast Neoplasms; Butyrylcholinesterase; Cannabis; Carbapenems; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Carboxylic Acids; Carcinoma, Hepatocellular; Cardiovascular Diseases; Carnitine; Case-Control Studies; Catalysis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Child; China; Cholinesterase Inhibitors; Clarithromycin; Clostridioides; Clostridioides difficile; Clostridium Infections; Cohort Studies; Colistin; Colitis; Colon; Coloring Agents; Coronary Artery Bypass; Creatinine; Crystalloid Solutions; Cytokines; Depression; Dextran Sulfate; Dextrans; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Diarrhea; Dietary Supplements; Diphenhydramine; Disease Models, Animal; Disease Outbreaks; Double-Blind Method; Doxorubicin; Drosophila; Drug Tapering; Dysbiosis; Electrons; Escherichia coli; Extracellular Vesicles; Fatigue; Female; Fermentation; gamma-Cyclodextrins; Gastrointestinal Microbiome; Glucose; Graft Survival; Graft vs Host Disease; Head and Neck Neoplasms; Heart Arrest, Induced; Hematopoietic Stem Cell Transplantation; High-Intensity Interval Training; Hippocampus; Humans; Hydrogen-Ion Concentration; Hypertension; Incidence; Interferon-gamma; Italy; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Lactoferrin; Larva; Length of Stay; Lignin; Liver; Liver Neoplasms; Liver Transplantation; Living Donors; Low Back Pain; Lung; Lung Volume Measurements; Macrophages; Male; Melphalan; Men; Mendelian Randomization Analysis; Meropenem; Methane; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mitochondrial Proteins; Molecular Docking Simulation; Molecular Structure; Mothers; Motivation; Mycoplasma; Mycoplasma hominis; Mycoplasma Infections; NAD; Nanocomposites; Nanoparticles; Nanotubes, Carbon; Naproxen; Neovascularization, Pathologic; Neurons; Nitrates; Nucleolin; Opuntia; Paratyphoid Fever; Phenotype; Phosphatidylinositol 3-Kinases; Phytochemicals; Plant Extracts; Pregnancy; Prevalence; Prospective Studies; Proto-Oncogene Proteins c-akt; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Wistar; Resveratrol; Retrospective Studies; Rifampin; Risk Factors; RNA, Messenger; Selenium; Sleep; Social Behavior; Soil; Soil Pollutants; Squamous Cell Carcinoma of Head and Neck; Staphylococcus aureus; Structure-Activity Relationship; Suicidal Ideation; Suicide; Superoxide Dismutase-1; Surveys and Questionnaires; Swimming; Syndrome; Tannins; Temperature; Transforming Growth Factor beta; Transplantation Conditioning; Treatment Outcome; Triple Negative Breast Neoplasms; Troponin T; Tumor Microenvironment; United Kingdom; Ureaplasma; Ureaplasma urealyticum; Urinary Tract Infections; Viscum; Waste Disposal Facilities; Wastewater; Water; Water Pollutants, Chemical; Wolfiporia; Young Adult	2022
Hydrogen Sulfide-Releasing Therapeutics: Translation to the Clinic. Antioxidants & redox signaling, 2018, 06-01, Volume: 28, Issue:16 Topics: Animals; Arthritis; Captopril; Cardiovascular Agents; Cardiovascular Diseases; Dose-Response Relationship, Drug; Humans; Hydrogen Sulfide; Naproxen	2018
[Cardiovascular risk of non-steroidal anti-inflammatory drugs]. Medicina, 2018, Volume: 78, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Drug Interactions; Humans; Ibuprofen; Naproxen; Risk Factors	2018
Vascular effects of nonsteroidal antiinflammatory drugs. Joint bone spine, 2013, Volume: 80, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Diclofenac; Humans; Naproxen; Primary Prevention; Risk Factors; Secondary Prevention	2013
[Cardiovascular and gastrointestinal safety of NSAIDs]. Nederlands tijdschrift voor geneeskunde, 2014, Volume: 158 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Gastrointestinal Diseases; Humans; Naproxen; Proton Pump Inhibitors	2014
Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen. Minerva cardioangiologica, 2014, Volume: 62, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Humans; Naproxen; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones	2014
[Cardiovascular side effects of non-steroidal anti-inflammatory drugs in the light of recent recommendations. Diclofenac is not more dangerous]. Orvosi hetilap, 2015, Mar-29, Volume: 156, Issue:13 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cardiovascular System; Diclofenac; Drug Interactions; Humans; Ibuprofen; Naproxen	2015
Elevation of cardiovascular risk by non-steroidal anti-inflammatory drugs. Trends in cardiovascular medicine, 2015, Volume: 25, Issue:8 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Cyclooxygenase 1; Cyclooxygenase 2; Female; Follow-Up Studies; Homeostasis; Humans; Lactones; Male; Middle Aged; Naproxen; Prevalence; Randomized Controlled Trials as Topic; Risk Assessment; Sulfones	2015
Clinical Pharmacology and Cardiovascular Safety of Naproxen. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2017, Volume: 17, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Humans; Naproxen; Substrate Specificity	2017
Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs. Current rheumatology reports, 2009, Volume: 11, Issue:1 Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Humans; Meta-Analysis as Topic; Naproxen; Risk Assessment; Risk Factors	2009
Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS medicine, 2011, Volume: 8, Issue:9 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Diclofenac; Humans; Ibuprofen; Naproxen	2011
Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective. Spine, 2013, May-15, Volume: 38, Issue:11 Topics: Age Factors; Aged; Amitriptyline; Analgesics; Cardiovascular Diseases; Celecoxib; Chronic Disease; Clinical Trials as Topic; Cost-Benefit Analysis; Duloxetine Hydrochloride; gamma-Aminobutyric Acid; Gastrointestinal Diseases; Humans; Hydromorphone; Low Back Pain; Markov Chains; Middle Aged; Models, Economic; Naproxen; Ontario; Osteoarthritis; Outcome Assessment, Health Care; Oxycodone; Pregabalin; Pyrazoles; Quality-Adjusted Life Years; Quebec; Sulfonamides; Thiophenes	2013
Reinitiating aspirin therapy for primary prevention of cardiovascular events in a patient post-aspirin-induced upper gastrointestinal bleed: a case report and review of literature. The Annals of pharmacotherapy, 2013, Volume: 47, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Interactions; Drug Monitoring; Gastrointestinal Hemorrhage; Humans; Male; Naproxen; Pantoprazole; Proton Pump Inhibitors; Treatment Outcome	2013
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. Journal of the American College of Cardiology, 2005, Apr-19, Volume: 45, Issue:8 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cardiovascular Diseases; Cyclooxygenase 1; Drug Interactions; Drug Therapy, Combination; Humans; In Vitro Techniques; Membrane Proteins; Naproxen; Platelet Aggregation; Prostaglandin-Endoperoxide Synthases; Thromboxane B2	2005
The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding. Journal of clinical pharmacology, 2005, Volume: 45, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cardiovascular Diseases; Confounding Factors, Epidemiologic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Membrane Proteins; Naproxen; Propionates; Prostaglandin-Endoperoxide Synthases; Randomized Controlled Trials as Topic	2005
[Do selective COX-2 inhibitors have adverse renal and cardiovascular effects?]. Praxis, 2005, Nov-23, Volume: 94, Issue:47 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Humans; Kidney Diseases; Naproxen; Pyrazoles; Risk Assessment; Sulfonamides; Thromboembolism	2005
The murky waters of the coxibs: a review of the current state of play. Inflammopharmacology, 2005, Volume: 13, Issue:4 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Endothelium, Vascular; Gastrointestinal Diseases; Humans; Naproxen; Risk Assessment	2005
Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences? Naunyn-Schmiedeberg's archives of pharmacology, 2006, Volume: 373, Issue:1 Topics: Cardiovascular Diseases; Celecoxib; Cell Proliferation; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Heart Failure; Hemostasis; Humans; Hypertension; Lactones; Naproxen; Natriuretic Peptide, Brain; Peptide Fragments; Pyrazoles; Sulfonamides; Sulfones	2006
NO-NSAIDs: from inflammatory mediators to clinical readouts. Inflammation & allergy drug targets, 2006, Volume: 5, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Blood Coagulation; Cardiovascular Diseases; Chemotaxis, Leukocyte; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Cytokines; Endothelial Cells; Gastrointestinal Tract; Gene Expression Regulation; Humans; Leukocytes; Macrophages; Mitochondria; Naproxen; Nitrates; Nitric Oxide; Nitric Oxide Synthase Type II; Platelet Aggregation	2006
Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. The American journal of medicine, 2006, Volume: 119, Issue:7 Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Humans; Joint Diseases; Naproxen; Randomized Controlled Trials as Topic; Risk Factors	2006
Sumatriptan: update and review. Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:11 Topics: Animals; Cardiovascular Diseases; Drug Interactions; Drug Tolerance; Humans; Naproxen; Sumatriptan; Treatment Outcome	2006
Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA, 2006, Oct-04, Volume: 296, Issue:13 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Lactones; Naproxen; Pyrazoles; Risk; Sulfonamides; Sulfones	2006
[What do we know about the cardiovascular toxicity of the NSAIDs?]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Follow-Up Studies; Humans; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors	2006
[Are the NSAIDs able to compromising the cardio-preventive efficacy of aspirin?]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Cyclooxygenase Inhibitors; Drug Interactions; Follow-Up Studies; Humans; Ibuprofen; MEDLINE; Middle Aged; Multivariate Analysis; Naproxen; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk; Thromboxane B2; Ticlopidine; Time Factors	2006
Celecoxib clinical profile. Rheumatology (Oxford, England), 2000, Volume: 39 Suppl 2 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Humans; Ibuprofen; In Vitro Techniques; Isoenzymes; Kidney Diseases; Membrane Proteins; Middle Aged; Naproxen; Osteoarthritis; Pain; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome	2000
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation, 2001, Nov-06, Volume: 104, Issue:19 Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Chronic Disease; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Comorbidity; Cyclooxygenase 1; Cyclooxygenase 2; Female; Humans; Isoenzymes; Lactones; Low Back Pain; Male; Membrane Proteins; Middle Aged; Naproxen; Osteoarthritis; Proportional Hazards Models; Prostaglandin-Endoperoxide Synthases; Randomized Controlled Trials as Topic; Risk; Sulfones; Thrombosis	2001

Trials

15 trial(s) available for naproxen and Cardiovascular Diseases

Article	Year
Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial. European heart journal. Cardiovascular pharmacotherapy, 2022, Sep-03, Volume: 8, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Humans; Ibuprofen; Naproxen; Prospective Studies	2022
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease. Medicina clinica (English ed.), 2022, Dec-23, Volume: 159, Issue:12 Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter Infections; Adaptation, Psychological; Adolescent; Adsorption; Adult; Aged; Alcohol Drinking; Alzheimer Disease; Amikacin; Ammonia; Anaerobiosis; Animals; Anorexia; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Anxiety; Aptamers, Nucleotide; Asthenia; Attention Deficit Disorder with Hyperactivity; Bacterial Proteins; Beryllium; beta-Lactamases; Biofuels; Biomass; Biosensing Techniques; Bismuth; Blister; Body Mass Index; Body Surface Area; Boronic Acids; Brain; Breast Neoplasms; Butyrylcholinesterase; Cannabis; Carbapenems; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Carboxylic Acids; Carcinoma, Hepatocellular; Cardiovascular Diseases; Carnitine; Case-Control Studies; Catalysis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Child; China; Cholinesterase Inhibitors; Clarithromycin; Clostridioides; Clostridioides difficile; Clostridium Infections; Cohort Studies; Colistin; Colitis; Colon; Coloring Agents; Coronary Artery Bypass; Creatinine; Crystalloid Solutions; Cytokines; Depression; Dextran Sulfate; Dextrans; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Diarrhea; Dietary Supplements; Diphenhydramine; Disease Models, Animal; Disease Outbreaks; Double-Blind Method; Doxorubicin; Drosophila; Drug Tapering; Dysbiosis; Electrons; Escherichia coli; Extracellular Vesicles; Fatigue; Female; Fermentation; gamma-Cyclodextrins; Gastrointestinal Microbiome; Glucose; Graft Survival; Graft vs Host Disease; Head and Neck Neoplasms; Heart Arrest, Induced; Hematopoietic Stem Cell Transplantation; High-Intensity Interval Training; Hippocampus; Humans; Hydrogen-Ion Concentration; Hypertension; Incidence; Interferon-gamma; Italy; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Lactoferrin; Larva; Length of Stay; Lignin; Liver; Liver Neoplasms; Liver Transplantation; Living Donors; Low Back Pain; Lung; Lung Volume Measurements; Macrophages; Male; Melphalan; Men; Mendelian Randomization Analysis; Meropenem; Methane; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mitochondrial Proteins; Molecular Docking Simulation; Molecular Structure; Mothers; Motivation; Mycoplasma; Mycoplasma hominis; Mycoplasma Infections; NAD; Nanocomposites; Nanoparticles; Nanotubes, Carbon; Naproxen; Neovascularization, Pathologic; Neurons; Nitrates; Nucleolin; Opuntia; Paratyphoid Fever; Phenotype; Phosphatidylinositol 3-Kinases; Phytochemicals; Plant Extracts; Pregnancy; Prevalence; Prospective Studies; Proto-Oncogene Proteins c-akt; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Wistar; Resveratrol; Retrospective Studies; Rifampin; Risk Factors; RNA, Messenger; Selenium; Sleep; Social Behavior; Soil; Soil Pollutants; Squamous Cell Carcinoma of Head and Neck; Staphylococcus aureus; Structure-Activity Relationship; Suicidal Ideation; Suicide; Superoxide Dismutase-1; Surveys and Questionnaires; Swimming; Syndrome; Tannins; Temperature; Transforming Growth Factor beta; Transplantation Conditioning; Treatment Outcome; Triple Negative Breast Neoplasms; Troponin T; Tumor Microenvironment; United Kingdom; Ureaplasma; Ureaplasma urealyticum; Urinary Tract Infections; Viscum; Waste Disposal Facilities; Wastewater; Water; Water Pollutants, Chemical; Wolfiporia; Young Adult	2022
Praxis, 2017, Volume: 106, Issue:8 Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Ibuprofen; Male; Naproxen; Osteoarthritis; Proton Pump Inhibitors; Survival Analysis; United States; United States Food and Drug Administration	2017
Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. Lancet (London, England), 2017, Jun-17, Volume: 389, Issue:10087 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Humans; Middle Aged; Naproxen; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Recurrence; Secondary Prevention	2017
Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial. Arthritis & rheumatology (Hoboken, N.J.), 2018, Volume: 70, Issue:4 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Ibuprofen; Kidney Diseases; Male; Middle Aged; Naproxen; Osteoarthritis; Risk Factors; Treatment Outcome	2018
Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial. Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:8 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Osteoarthritis; Reproducibility of Results; Risk Assessment; Risk Factors	2019
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. The New England journal of medicine, 2016, 12-29, Volume: 375, Issue:26 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Gastrointestinal Diseases; Humans; Ibuprofen; Intention to Treat Analysis; Kidney Diseases; Male; Middle Aged; Naproxen; Risk	2016
Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. American heart journal, 2009, Volume: 157, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Humans; Ibuprofen; Middle Aged; Naproxen; Prospective Studies; Pyrazoles; Sulfonamides; Treatment Outcome	2009
Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT. PloS one, 2010, Feb-19, Volume: 5, Issue:2 Topics: 6-Ketoprostaglandin F1 alpha; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Drug Therapy, Combination; F2-Isoprostanes; Female; Humans; Male; Naproxen; Pyrazoles; Sulfonamides; Thromboxane B2; Treatment Outcome	2010
Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Annals of internal medicine, 2003, Oct-07, Volume: 139, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Humans; Hypertension; Lactones; Male; Middle Aged; Naproxen; Osteoarthritis; Prospective Studies; Sulfones	2003
Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Annals of the rheumatic diseases, 2007, Volume: 66, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Double-Blind Method; Etoricoxib; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Naproxen; Osteoarthritis; Pain Measurement; Pyridines; Sulfones; Time Factors; Treatment Outcome	2007
Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Annals of the rheumatic diseases, 2007, Volume: 66, Issue:6 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Female; Heart Defects, Congenital; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Osteoarthritis	2007
Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2007, Volume: 5, Issue:10 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Confidence Intervals; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Lansoprazole; Male; Middle Aged; Naproxen; Osteoarthritis; Proton Pump Inhibitors; Pyrazoles; Retrospective Studies; Risk Factors; Stomach Ulcer; Sulfonamides; United States	2007
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. The New England journal of medicine, 2000, 11-23, Volume: 343, Issue:21 Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Duodenal Obstruction; Female; Gastric Outlet Obstruction; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Humans; Isoenzymes; Lactones; Male; Membrane Proteins; Middle Aged; Naproxen; Peptic Ulcer; Proportional Hazards Models; Prostaglandin-Endoperoxide Synthases; Sulfones	2000
A double-blind multicentre trial of piroxicam and naproxen in osteoarthritis. Clinical rheumatology, 1986, Volume: 5, Issue:1 Topics: Aged; Cardiovascular Diseases; Central Nervous System Diseases; Clinical Trials as Topic; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Naproxen; Osteoarthritis; Pain; Piroxicam; Thiazines	1986

Other Studies

32 other study(ies) available for naproxen and Cardiovascular Diseases

Article	Year
Interactions of Nonsteroidal Antiinflammatory Drugs and Aspirin and Risk of Cardiovascular Disease in Patients With Osteoarthritis. American journal of epidemiology, 2023, 09-01, Volume: 192, Issue:9 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans; Ibuprofen; Naproxen; Osteoarthritis	2023
Impact of Lifestyle and Socioeconomic Position on the Association Between Non-steroidal Anti-inflammatory Drug Use and Major Adverse Cardiovascular Events: A Case-Crossover Study. Drug safety, 2023, Volume: 46, Issue:6 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cross-Over Studies; Diclofenac; Humans; Ibuprofen; Life Style; Myocardial Infarction; Naproxen; Risk Factors; Socioeconomic Factors	2023
Cardiovascular risks of continuing vs. initiating NSAIDs after first-time myocardial infarction or heart failure: a nationwide cohort study. European heart journal. Cardiovascular pharmacotherapy, 2023, 09-20, Volume: 9, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cohort Studies; Diclofenac; Heart Disease Risk Factors; Heart Failure; Humans; Ibuprofen; Myocardial Infarction; Naproxen; Risk Factors	2023
Evaluation of cardiovascular risk associated with SKI306X use in patients with osteoarthritis and rheumatoid arthritis. Journal of ethnopharmacology, 2017, Jul-31, Volume: 207 Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Cohort Studies; Drugs, Chinese Herbal; Female; Humans; Incidence; Male; Middle Aged; Naproxen; Osteoarthritis; Retrospective Studies; Risk Factors; Time Factors; Young Adult	2017
Non-inferiority versus superiority drug claims: the (not so) subtle distinction. Trials, 2017, 06-15, Volume: 18, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Data Interpretation, Statistical; Drug Approval; Drug Therapy; Equivalence Trials as Topic; Humans; Ibuprofen; Models, Statistical; Naproxen; Research Design; Risk Assessment; Risk Factors; Treatment Outcome	2017
Diclofenac use and cardiovascular risks: series of nationwide cohort studies. BMJ (Clinical research ed.), 2018, Sep-04, Volume: 362 Topics: Acetaminophen; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cohort Studies; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Propensity Score; Risk Factors	2018
NSAID choice: lessons from PRECISION. Aging, 2019, 04-29, Volume: 11, Issue:8 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Humans; Ibuprofen; Naproxen; Pain; Treatment Outcome	2019
Physicians should be cautious when prescribing diclofenac. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2013, Apr-02, Volume: 185, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Diclofenac; Drug and Narcotic Control; Humans; Naproxen; Risk Factors	2013
More pain for painkillers. Time, 2013, Jun-24, Volume: 181, Issue:24 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Humans; Ibuprofen; Naproxen; Pain; Pyrazoles; Risk Factors; Safety-Based Drug Withdrawals; Sulfonamides; United States; United States Food and Drug Administration	2013
Cardiovascular safety of NSAIDs. Canadian family physician Medecin de famille canadien, 2014, Volume: 60, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Ibuprofen; Naproxen	2014
Anti-inflammatory and cytoprotective properties of hydrogen sulfide. Methods in enzymology, 2015, Volume: 555 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cystathionine beta-Synthase; Cystathionine gamma-Lyase; Gastrointestinal Tract; Gene Expression Regulation; Humans; Hydrogen Sulfide; Inflammation; Inflammatory Bowel Diseases; Intestinal Mucosa; Naproxen; Neurodegenerative Diseases; Pain; Protective Agents; Signal Transduction; Spinal Cord Injuries	2015
NSAIDs and serious cardiovascular disorders: especially cox-2 inhibitors and diclofenac. Prescrire international, 2016, Volume: 25, Issue:167 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Ibuprofen; Naproxen	2016
Inflammation: NSAIDs and cardiovascular risk in arthritis. Nature reviews. Cardiology, 2017, Volume: 14, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Humans; Ibuprofen; Inflammation; Naproxen; Risk Factors	2017
Rates of Nonsteroidal Anti-Inflammatory Drug Use in Patients with Established Cardiovascular Disease: A Retrospective, Cross-Sectional Study from NHANES 2009-2010. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2017, Volume: 17, Issue:3 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cross-Sectional Studies; Female; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Nutrition Surveys; Prescription Drugs; Retrospective Studies	2017
Aspirin, NSAIDs, and cardiovascular risk: is there a link? The American journal of medicine, 2008, Volume: 121, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Interactions; Humans; Naproxen	2008
Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circulation. Cardiovascular quality and outcomes, 2009, Volume: 2, Issue:3 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; Coronary Artery Disease; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Follow-Up Studies; Hospitalization; Humans; Ibuprofen; Incidence; Lactones; Male; Middle Aged; Myocardial Infarction; Naproxen; Outpatients; Pyrazoles; Retrospective Studies; Risk Factors; Stroke; Sulfonamides; Sulfones; Tennessee	2009
Summaries for patients. Gastrointestinal side effects of rofecoxib and naproxen. Annals of internal medicine, 2003, Oct-07, Volume: 139, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Humans; Hypertension; Lactones; Male; Middle Aged; Naproxen; Osteoarthritis; Prospective Studies; Sulfones	2003
[New evaluation by the EU approval committee. Benefits of cox-2 inhibitors outweigh possible risks (interview by Dr. Thomas Meissner)]. MMW Fortschritte der Medizin, 2004, Feb-26, Volume: 146, Issue:9 Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Approval; Europe; European Union; Humans; Naproxen; Product Surveillance, Postmarketing; Risk Assessment	2004
Coxibs and cardiovascular disease. The New England journal of medicine, 2004, Oct-21, Volume: 351, Issue:17 Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Epoprostenol; Gastrointestinal Diseases; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Naproxen; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk; Sulfonamides; Sulfones; Thromboxane A2; United States; United States Food and Drug Administration	2004
The withdrawal of rofecoxib. Pharmacoepidemiology and drug safety, 2005, Volume: 14, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Death, Sudden, Cardiac; Drug Industry; Humans; Lactones; Naproxen; Pharmacoepidemiology; Product Surveillance, Postmarketing; Sulfones	2005
Arthritis medications and cardiovascular events. JAMA, 2005, Apr-27, Volume: 293, Issue:16 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Humans; Legislation, Drug; Naproxen	2005
Report of specific cardiovascular outcomes of the ADVANTAGE trial. Annals of internal medicine, 2005, Jul-19, Volume: 143, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Humans; Lactones; Naproxen; Osteoarthritis; Sulfones	2005
The lessons of Vioxx. The New England journal of medicine, 2005, Sep-29, Volume: 353, Issue:13 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Industry; Gastrointestinal Diseases; Humans; Lactones; Marketing; Naproxen; Product Surveillance, Postmarketing; Sulfones; United States; United States Food and Drug Administration	2005
Expression of concern reaffirmed. The New England journal of medicine, 2006, Mar-16, Volume: 354, Issue:11 Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Lactones; Myocardial Infarction; Naproxen; Research Design; Sulfones; Thromboembolism	2006
Response to expression of concern regarding VIGOR study. The New England journal of medicine, 2006, Mar-16, Volume: 354, Issue:11 Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Data Interpretation, Statistical; Gastrointestinal Diseases; Humans; Lactones; Myocardial Infarction; Naproxen; Sulfones	2006
Lessons to learn from the COX-2 saga. Yes, FDA reforms are needed. And marketing distorts how medications are used. But one moral to the story is that all drugs have risks. Harvard health letter, 2005, Volume: 30, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug-Related Side Effects and Adverse Reactions; Humans; Isoxazoles; Lactones; Marketing of Health Services; Naproxen; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug safety, 2006, Volume: 29, Issue:7 Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Etodolac; Female; Humans; Ibuprofen; Lactones; Male; Middle Aged; Naproxen; Pyrazoles; Sulfonamides; Sulfones; Time Factors; United States; Veterans	2006
Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level. Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Computer Simulation; Coronary Disease; Cyclooxygenase Inhibitors; Diclofenac; Female; Heart Failure; Humans; Ibuprofen; Male; Middle Aged; Models, Statistical; Naproxen; Peptic Ulcer; Population Surveillance; Pyrazoles; Risk Assessment; Risk Factors; Stroke; Sulfonamides; United States	2007
[Overestimated]. Medizinische Klinik (Munich, Germany : 1983), 2006, Aug-15, Volume: 101, Issue:8 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Lactones; Myocardial Infarction; Naproxen; Odds Ratio; Risk; Risk Assessment; Stroke; Sulfones	2006
Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain. Prescrire international, 2007, Volume: 16, Issue:92 Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Gastrointestinal Diseases; Gout; Humans; Ibuprofen; Naproxen; Pain; Pyridines; Sulfones	2007
Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease. Journal of cardiovascular pharmacology and therapeutics, 2008, Volume: 13, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Humans; Ibuprofen; Meta-Analysis as Topic; Myocardial Infarction; Naproxen; Risk	2008
Interim report: National Registry of Possible Drug-Induced Ocular Side Effects. Ophthalmology, 1979, Volume: 86, Issue:1 Topics: Aged; Anesthetics, Local; Carbonic Anhydrase Inhibitors; Cardiovascular Diseases; Diazepam; Dietary Proteins; Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Female; Fluorides, Topical; Humans; Infant; Middle Aged; Naproxen; Phenylephrine; Registries; Thiabendazole	1979